IDiyas

For the Inventor, By the Inventor

Allentown, PA, United States of America

Lizhen He

USPTO Granted Patents = 15 

 

 

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 85(Granted Patents)


Location History:

  • Allentown, PA (US) (2012 - 2021)
  • Fujian, CN (2022)
  • Zhenghe County, CN (2022)

Company Filing History:

goldMedal15 out of 45 
 
Celldex Therapeutics Limited
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 12297266 - Agonistic antibodies that bind human CD40 and uses thereof (2025-05-13),
2. 11459393 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-10-04),
3. 11332537 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-05-17),
4. 11180566 - Antibodies that bind human CD27 and uses thereof (2021-11-23),
5. 10941201 - Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies (2021-03-09),
6. 10865244 - Nucleic acids encoding agonistic antibodies that bind CD40 (2020-12-15),
7. 10633444 - Agonistic antibodies that bind CD40 (2020-04-28),
8. 9624300 - Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) (2017-04-18),
9. 9259459 - Antibody vaccine conjugates and uses therefor (2016-02-16),
10. 9243064 - Antibody vaccine conjugates and uses therefor (2016-01-26),
11. 9169325 - Antibodies that bind human CD27 and uses thereof (2015-10-27),
12. 8586720 - Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) (2013-11-19),
13. 8362214 - Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) (2013-01-29),
14. 8318165 - Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP) (2012-11-27),
15. 8236318 - Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) (2012-08-07),

Title: The Innovations of Lizhen He: A Trailblazer in Therapeutic Antibodies

Introduction: Lizhen He, an accomplished inventor based in Allentown, PA, has made significant contributions to the field of therapeutic antibodies. With a remarkable portfolio of 15 patents, He demonstrates a commitment to advancing immunotherapy and enhancing patient outcomes through innovative solutions.

Latest Patents: Among his latest innovations are groundbreaking patents focusing on agonistic antibodies that bind to human CD40. This includes the disclosure of isolated monoclonal agonistic antibodies and related antibody-based compositions, which hold promise in therapeutic and diagnostic applications. Additionally, He has developed patents for anti-CD27 and anti-PD-L1 antibodies, as well as bispecific constructs. These inventions involve methods for stimulating T cell activity and enhancing immune responses, addressing critical diseases and conditions through effective treatment options.

Career Highlights: Lizhen He has cultivated his career at Celldex Therapeutics Limited, a company renowned for its pioneering work in immunotherapy. His role in the development of innovative therapies showcases his expertise and dedication to finding solutions that improve clinical outcomes for patients.

Collaborations: Throughout his career, He has collaborated with esteemed colleagues, including Tibor P. Keler and Laura A. Vitale. These partnerships reflect a strong team dynamic and commitment to research excellence in the field of therapeutic antibodies.

Conclusion: Lizhen He's contributions to the world of antibodies and immunotherapy underscore the importance of innovation in healthcare. His patents not only highlight his inventive spirit but also pave the way for future advancements that could transform treatment paradigms for numerous diseases. As a leading figure in the biotechnology sector, He continues to inspire colleagues and future inventors alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…